Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Elixinol Global.
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Cannabis may be the answer for this wilting WA coal mining town
Escrow Watch
Escrow Watch: The wait for that Elixinol sell off begins
Health & Biotech
The US legal pot market is massive and confusing: report
Health & Biotech
Weed Week: Canadians sunk some serious cash into reefer this year
Escrow Watch
Escrow Watch: Elixinol boss says he’s not selling his 56pc – yet
News
Lunchtime ASX small cap wrap: It’s ‘game on’ this morning
Health & Biotech
Biotech: Pesky pimple-like rosacea to get Botanix’s Permetrex treatment in early study
IPO Watch
IPO Watch: shhhh… there’s a new kid in town from Israel
Health & Biotech
Cannabis: Elixinol cops $2.2m profit hit on Japanese divestment
News
Hot Money Monday: These are the most in-demand stocks on the ASX right now
Health & Biotech
Dr Boreham’s Crucible: Elixinol says FDA hemp call an ‘inflexion point’ for industry
News
Weed Week: American pot could be worth $60 billion by 2025
News
Weed Week: Oz gets serious with medical marijuana, new clinics rolling out soon
News
Weed Week: US looks at ways to help cannabis players get banking access
News
Weed week: cannabis is about to get scary in Canada
Health & Biotech
The Pot Seat distilled: The 9 key things we know now about Aussie cannabis
Health & Biotech